Meeting
2016 Gastrointestinal Cancers Symposium
Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the GERCOR index.
Authors
Osamu Muto
Department of Medical Oncology, Japanese Red Cross Akita Hospital, Akita, Japan
Osamu Muto , Satoshi Yuki , Tetsuhito Muranaka , Takashi Kato , Takashi Meguro , Michio Nakamura , Atsushi Sato , Ichiro Iwanaga , Minoru Uebayashi , Miki Tateyama , Kazuteru Hatanaka , Kazunori Eto , Hiroyuki Okuda , Susumu Sogabe , Masakazu Abe , Kanji Kato , Sosuke Kato , Kencho Miyashita , Yuh Sakata , Yoshito Komatsu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 743)
DOI
10.1200/jco.2016.34.4_suppl.743
Abstract #
743
Poster Bd #
M18
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real-world comparison of triplet- versus doublet-chemotherapy with bevacizumab in patients with newly diagnosed metastatic colorectal cancer (mCRC).
First Author: William Joseph Chapin
Poster
2023 ASCO Annual Meeting
Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial.
First Author: Kathrin Heinrich
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz